Oncolytic Measles Virus Retargeting by Ligand Display
Despite significant advances in recent years, treatment of metastatic malignancies remains a significant challenge. There is an urgent need for development of novel therapeutic approaches. Virotherapy approaches have considerable potential, and among them
- PDF / 4,336,423 Bytes
- 245 Pages / 504.57 x 720 pts Page_size
- 8 Downloads / 189 Views
IN
MOLECULAR BIOLOGY™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For further volumes: http://www.springer.com/series/7651
wwwwwwwwwwwwwwwwww
Oncolytic Viruses Methods and Protocols
Edited by
David H. Kirn Jennerex Inc., San Francisco, CA, USA and University of Oxford School of Medicine, Oxford, UK
Ta-Chiang Liu The Johns Hopkins University Medical Center, Baltimore, MD, USA and Washington University in St. Louis, St. Louis, MO, USA
Steve H. Thorne Department of Surgery and Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
Editors David H. Kirn, MD Jennerex Inc. San Francisco, CA, USA and University of Oxford School of Medicine Oxford, UK [email protected]
Ta-Chiang Liu The Johns Hopkins University Medical Center Baltimore, MD, USA and Washington University in St. Louis St. Louis, MO, USA [email protected]
Steve H. Thorne, Ph.D. Department of Surgery and Immunology University of Pittsburgh Cancer Institute University of Pittsburgh Pittsburgh, PA, USA [email protected]
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-61779-339-4 e-ISBN 978-1-61779-340-0 DOI 10.1007/978-1-61779-340-0 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011936969 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Cover illustration: Springer Images Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface Since the first report of an engineered oncolytic virus by Martuza et al. two decades ago, there has been a continuing and steady increase of interest in the field. The keyword “oncolytic virus” is associated with nearly 300 publications from Pubmed in the year of 2009 alone. Herpes simplex virus (HSV) and adenovirus (Ad) were among the first virus species to be engineered for oncolytic purposes, while the spectrum of virus species tested has since broadened to include vesicular stomatitis virus (VSV), reovirus, myxoma virus, vaccinia virus, measles virus, and Newcastle disease virus (NDV), among others. Although several of these virus species are inherently tumor-selective, others rely on attenuating or tumor-targeting modifications. During the early days of development, the majority of the assay
Data Loading...
